ArticleCureus2025
Advancing Accuracy in Non-invasive Hemoglobin Estimation: A Comparative Clinical Study of the Performance of the Non-invasive Anemia Detection App (NiADA).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Non-invasive estimation of hemoglobin using machine learning algorithms from i-PPG and PPG signals.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnemia remains a significant global health burden, particularly in low- and middle-income countries. Traditional hemoglobin screening methods are invasive, resource-intensive, and often impractical for large-scale or repeated population-level screening. The Non-invasive Anemia Detection App (NiADA, Monere AI Private Limited, Kolkata, West Bengal, India) provides a smartphone-based, artificial intelligence (AI)-powered alternative for estimating hemoglobin levels using images of the lower palpebral conjunctiva.
objectiveThis study aims to evaluate the improvement in accuracy and clinical utility of NiADA version 3 compared to NiADA version 2 in estimating hemoglobin levels and detecting anemia across diverse demographic subgroups in a tertiary care setting. MATERIALS AND
methodsThis study was conducted at NRS Medical College and Hospital, Kolkata, India, from December 2024 to January 2025. A total of 2,476 participants (ages 2-90 years) were enrolled. Trained personnel captured partial facial images, focusing on the lower eyelid, using Android smartphones running NiADA version 3. The algorithm subsequently extracted the lower palpebral conjunctiva and surrounding scleral regions for automated analysis. Images underwent preprocessing and were analyzed in real time by the AI model. Venous blood samples were collected immediately after image capture in standard ethylenediamine tetraacetic acid anticoagulant tubes, and hemoglobin levels were measured using an automated hematology analyzer. Regression and classification performance were evaluated using Bland-Altman analysis, mean bias, Lin's concordance correlation coefficient (CCC), and confusion matrices. Subgroup analyses were performed for adult males, adult females, and children.
resultsNiADA exhibited strong agreement with laboratory-measured hemoglobin levels across all demographic subgroups, with Pearson correlation coefficients ranging from 0.81 to 0.86, Lin's CCC between 0.80 and 0.87, and R² values spanning 0.73 to 0.76. The mean bias remained within ±0.27 g/dL across cohorts. Bland-Altman analysis showed that over 95% of predictions fell within the limits of agreement for children (-2.07 to 2.46 g/dL), females (-2.48 to 2.64 g/dL), and males (-2.51 to 3.05 g/dL). In anemia classification, NiADA achieved the highest accuracy in adult females (88.7%), followed by children (84.4%) and adult males (81.2%). Sensitivity remained consistently high across all groups (≥88%), while specificity ranged from 71.8% to 76.1%.
conclusionsNiADA version 3 demonstrates strong accuracy and reliability as a non-invasive hemoglobin estimation tool, with performance comparable to that of conventional point-of-care devices. Its smartphone-based, consumable-free workflow makes it particularly well-suited for large-scale screening and longitudinal monitoring in both clinical and community settings. These results support NiADA's integration into public health initiatives targeting anemia surveillance and prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.